Table 37 Mirtazapine for children and adolescents with avoidant/restrictive food intake disorder
From: Canadian practice guidelines for the treatment of children and adolescents with eating disorders
Certainty assessment | Impact | Certainty | Importance | ||||||
|---|---|---|---|---|---|---|---|---|---|
№ of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | |||
Mealtime Anxiety (assessed with: clinical impression) | |||||||||
1 | Case Series | very serious a | not serious | not serious | not serious | none | Retrospective chart review of 14 cases pre and post documentation of rate of weight gain pre and post mirtazapine. Rate of gain significantly greater after mirtazapine (mean dose 25.5 mg). | ⨁◯◯◯ VERY LOW | CRITICAL |
Anxiety | |||||||||
1 | Case Report | very serious a | not serious | not serious | not serious | none | Single case report of 10 yo girl with ARFID and OCD treated with 15 mg/day of mirtazapine. Anxiety improved and she began to eat solid food within 1–2 weeks. | ⨁◯◯◯ VERY LOW | CRITICAL |